Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II bcr-abl peptide vaccine in CML
NCT00004052Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 1999
- Primary completion
- Aug 2005
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CMLVAX100 in chronic myelogenous leukemia (CML), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 1999; status: completed.
02
Drugs
CMLVAX100
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NCT00004052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004052.